These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 3641325)

  • 1. [Anti-HTLV III antibodies in the personnel of a hospital in the Campania region].
    Ferro V; Sapia P; Perna C; Salvi MP; Piscopo V
    Quad Sclavo Diagn; 1986 Mar; 22(1):104-9. PubMed ID: 3641325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibodies anti-HTLV III and lymphocyte subsets of high risk subjects.
    Ripa S; Mignini F; Anichini M; Casprini P; Prenna M
    Boll Ist Sieroter Milan; 1987; 66(2):101-5. PubMed ID: 3663335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunological profile of drug addicts: HTLV-III negative, HTLV-III positive and those with lymphadenopathy syndrome-AIDS related complex].
    Cascavilla N; Martini E; Melillo L; Musto P; Nobile M; Valori VM; Di Giorgio G; Carotenuto M
    Recenti Prog Med; 1987 Mar; 78(3):108-12. PubMed ID: 3648856
    [No Abstract]   [Full Text] [Related]  

  • 4. [Serological survey on the prevalence of anti-HTLV-III antibodies in a psychiatric hospital].
    Antila CC; Blotta MH; Gomes MC
    Rev Paul Med; 1986; 104(6):328. PubMed ID: 3650926
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prevalence of anti-HTLV III antibodies in detainees at the jail in Perugia].
    Stagni G; Francisci D; Pegiati R; Baldelli F
    Boll Ist Sieroter Milan; 1987; 66(6):453-5. PubMed ID: 3453148
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prevalence of antibodies against HTLV-III in the at risk population in Madrid. Clinical study and incidence of virologic markers].
    González Lahoz JM; Gutiérrez Angulo MT; Polo Rodríguez R; Subirats Núñez M; Moreno Celda V; Baquero Mochales M
    Rev Clin Esp; 1987 May; 180(8):416-9. PubMed ID: 3649830
    [No Abstract]   [Full Text] [Related]  

  • 7. [Screening of patients for HIV infection for prevention of the contamination of health care personnel in hospitals].
    Verbrugh HA
    Ned Tijdschr Geneeskd; 1987 Nov; 131(48):2207-8. PubMed ID: 3479702
    [No Abstract]   [Full Text] [Related]  

  • 8. Significance of anti-HTLV-III testing of volunteer blood donors.
    Grindon AJ
    Beitr Infusionther Klin Ernahr; 1987; 18():1-5. PubMed ID: 3326580
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence of antibodies to HTLV-III in AIDS risk groups in West Germany.
    Erfle V; Hehlmann R; Mellert W; Krüger G; Seifried E; Heimpel H; Rasokat H; Lechler E; Holzer E; Hellstern P
    Cancer Res; 1985 Sep; 45(9 Suppl):4627s-4629s. PubMed ID: 3860292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prevalence of anti-HTLV-III antibodies in volunteer blood donors in Guipuzcoa].
    Cortés A; Francisco C; Larrañaga MJ; Cárdenas JM
    Med Clin (Barc); 1987 Jan; 88(1):38-9. PubMed ID: 3644127
    [No Abstract]   [Full Text] [Related]  

  • 11. Detection of anti-HTLV III: modification of a commercial enzyme immunoassay.
    Barr A; Muir W; Dow BC; Arnott J; Macvarish IP
    Med Lab Sci; 1987 Jan; 44(1):97-9. PubMed ID: 3309535
    [No Abstract]   [Full Text] [Related]  

  • 12. [Visceral leishmaniasis associated with positive anti-HTLV III antibody].
    Verdejo J; Alvar J; Polo RM; González Lahoz JM
    Rev Clin Esp; 1987 Mar; 180(4):221. PubMed ID: 3647541
    [No Abstract]   [Full Text] [Related]  

  • 13. Computerised anti-HTLV-III data collection and integration.
    Houston SR; Barr A
    Med Lab Sci; 1986 Oct; 43(4):340-3. PubMed ID: 3477676
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunologic abnormalities and antibodies to HTLV-III in asymptomatic drug addicts.
    Ortona L; Laghi V; Tamburrini E; Nervo P; Cauda R
    Ala J Med Sci; 1987 Jan; 24(1):46-51. PubMed ID: 3644604
    [No Abstract]   [Full Text] [Related]  

  • 15. HTLV-III antibodies in a patient with mycosis fungoides.
    Srivastava BI; Getchell JP; Stoll HL
    J Med; 1986; 17(1):57-63. PubMed ID: 3473157
    [No Abstract]   [Full Text] [Related]  

  • 16. Neutralizing antibodies in HIV (HTLV-III) infection: correlation with clinical outcome and antibody response against different viral proteins.
    Ranki A; Weiss SH; Valle SL; Antonen J; Krohn KJ
    Clin Exp Immunol; 1987 Aug; 69(2):231-9. PubMed ID: 3652531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological changes in beta-thalassemia major patients positive for HTLV-III antibodies.
    Romeo MA; Russo Mancuso G; Mauro L; Sciotto A; Romeo MA; Di Gregorio F; Giammanco G; Schiliro G
    Eur J Epidemiol; 1987 Dec; 3(4):451-3. PubMed ID: 3500869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HTLV-III: the etiologic agent of AIDS.
    Sarngadharan MG; DeVico AL; Bruch L; Schüpbach J; Gallo RC
    Princess Takamatsu Symp; 1984; 15():301-8. PubMed ID: 6100648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Prevalence of anti-HTLV-III antibodies in blood donors and risk populations in Zaragoza].
    Callén L; Gutiérrez M; Lasierra P; Larrad L
    Med Clin (Barc); 1986 Jun; 87(2):82. PubMed ID: 3461230
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence of occult hepatitis B & C in HIV patients infected through sexual transmission.
    Rai RR; Mathur A; Mathur D; Udawat HP; Nepalia S; Nijhawan S; Mathur A
    Trop Gastroenterol; 2007; 28(1):19-23. PubMed ID: 17896605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.